Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the champion crab stocks to put successful now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by aggregate value-creating regulatory catalysts.

ldutko/Shutterstock.com

In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib successful patients with Gastrointestinal Stromal Tumors (GIST). Consequently, the institution submitted to the FDA, having already secured Breakthrough Therapy Designation.

The slate of affirmative regulatory milestones comes connected the campaigner cause showing wide objective payment crossed each grounds domains. Cogent Biosciences is connected the cusp of launching bezuclastinib successful the 2nd fractional of 2026, awaiting FDA approval.

Six Abstracts from the SUMMIT proceedings of bezuclastinib successful patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) person already been accepted for presumption astatine the 2026 AAAAI yearly meeting.

Cogent Biosciences exited 2025 with $900.8 cardinal successful currency equivalents and marketable securities, having repaid $54.8 cardinal of semipermanent indebtedness successful the 4th quarter. Research and improvement expenses accrued to $75.6 cardinal successful the 4th fourth of 2025 from $62 cardinal successful the 4th fourth of 2024.

On the different hand, full-year R&D totaled $269.8 million, up from $232.7 cardinal successful 2024. Net nonaccomplishment widened to $102.5 cardinal successful the 4th fourth and to $328.9 cardinal for the afloat twelvemonth 2025, compared to $67.9 cardinal and $255.9 cardinal for the 4th fourth and afloat twelvemonth 2024, respectively .

Cogent Biosciences Inc. (NASDAQ:COGT) is simply a clinical-stage biotechnology institution focused connected processing precision therapies for genetically defined diseases. Their superior cause candidate, bezuclastinib (CGT9486), is simply a potent, selective inhibitor designed to dainty systemic mastocytosis and precocious gastrointestinal stromal tumors (GIST) by targeting the KIT D816V mutation.

While we admit the imaginable of COGT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey connected Google News.